CDKN1A and acute myeloid leukemia: Interestingly, there was also an induction of CDKN1A expression in OCI-AML2 and MV4-11 cells treated with 50 nM cobimetinib, but not in MOLM13 cells, indicating that MEK inhibition can lead to p53 activation, at least in some AML cells.